CorEvitas-Specialty EMR Data’s Post

We're excited to share poster presentations at the upcoming AMCP Nexus 2024 meeting in Las Vegas! #AMCPNexus #RWE

Using high-quality, fit-for-purpose real-world evidence and research, we empower our partners to recognize and address health inequities in clinical development and assessment. Learn more on how we reduced inequities within breast cancer among women in UK, and browse our other recent work in supporting health equity >> https://hubs.la/Q02RLMcW0 #breastcancerawareness #RWD #RWE

📣📈‼️We’re excited to announce the launch of our new adolescent atopic dermatitis (AD) clinical registry! This registry addresses a critical unmet need for real-world evidence (#RWE) and adolescent-specific developmental and safety data related to novel therapies for AD. It complements the existing adult AD registry and expands our geographic footprint to the European Union. Read the press release for full details! https://hubs.la/Q02RvPJ50 #atopicdermatitis #atopiceczemaunfiltered #RWD

Our #RealWorldData is shaping the future of #maternalhealth, creating a foundation for healthier beginnings for every mother and baby. Learn how our next-gen pregnancy registries can support your study, from design and data analysis to real-time reports, whilst ensuring data hygiene and participation engagement. 💡Learn more >> https://hubs.la/Q02Q26xF0

#AtopicEczemaAwarenessDay and every day, we proudly work towards advancing research and improving quality of life for patients living with atopic eczema, a condition that affects about 20% of children and 10% of adults globally. Our atopic dermatitis registry, which follows over 4,210 patients longitudinally, studies the natural history of AD, the real-world effectiveness and safety of medications, and clinician- and patient-reported outcomes. #WorldAtopicEczemaDay #atopicdermatitis #eczema Learn more about our AD registry >> https://hubs.la/Q02NG0WC0

🔊 Peter Wahl, our Global Head of Scientific Affairs, unpacks the world of #ClinicalRegistries in just 10 minutes, offering insights on registry purposes, options like multi-sponsor and bespoke registries, and real-world examples of our registry data in action! Peter also shares questions to consider when selecting the type of registry that best fits your study needs. Make your next coffee break a productive one! ☕ Click to view the full video ▶ https://hubs.la/Q02Pm1Pw0 #RealWorldData #ResearchInsights

September is Alopecia Areata Awareness Month! Alopecia is a common autoimmune disorder affecting about 2 in every 1,000 people. Our alopecia areata registry is the first of its kind for this disorder, designed to study the natural history of AA, the real-world effectiveness and safety of medications, and clinician- and patient-reported outcomes. Through the registry, we aim to advance medical research and improve quality of life for patients living with AA. #AlopeciaAwarenessMonth #clinicalregistry #RWD #RWE https://hubs.la/Q02Nw3Kl0

September is Rheumatic Disease Awareness Month! 💜💙 Do you know that of over 200 identified rheumatic diseases, the most common are arthritis and lupus? Our rheumatoid arthritis registry is the largest real-world prospective cohort study in the world, tracking both clinical and patient reported outcomes. By bringing together large #datasets and analyzing patterns in treatments and outcomes, we empower our pharma partners with evidence that drives decision making in research to improve the patient experience. #rheumaticdisease #rheumatoidarthritis #clinicalregistry #RWD #RWE https://hubs.la/Q02NzH7z0

Join our colleagues at Evidera for an insightful webinar on Wednesday, September 11 about the value of in-trial data for regulatory and HTA decision-making. 🌟REGISTER TODAY!🌟

This week in Berlin for #ISPEAnnual2024 has been nothing short of incredible - full of engaging conversations and invaluable new connections! Grateful for the opportunity to collaborate with such innovative minds and excited for what's next. Diego Wyszynski, Angie Vasco, Peter Wahl Jennifer Davidson